

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-24 (canceled)

25. (currently amended) A recombinant antibody, or an antigen binding fragment thereof, which ~~selectively~~ specifically binds to a modified integrin I-domain in the open conformation, relative to a modified integrin I-domain in the closed conformation.

26. (previously presented) The antibody of claim 25, or an antigen binding fragment thereof, which binds to an activation specific epitope on the integrin I-domain.

27. (previously presented) The antibody of claim 25, or an antigen binding fragment thereof, which blocks an interaction between an integrin and a cognate ligand.

28. (previously presented) The antibody of claim 25, or an antigen binding fragment thereof, further comprising a pharmaceutically acceptable carrier.

29. (previously presented) The antibody of claim 25, or an antigen binding fragment thereof, wherein said antibody is an anti-LFA-1 antibody.

30. (currently amended) A recombinant anti-~~LFA-1~~ integrin antibody, or an antigen binding fragment thereof, which ~~selectively~~ specifically binds to an ~~LFA-1~~ integrin I-domain in the open conformation, relative to an integrin I-domain in the closed conformation.

Claims 31-72 (canceled)

73. (currently amended) The antibody of claim 25, or an antigen binding fragment thereof, wherein said antibody, or antigen binding fragment thereof, selectively specifically binds to a modified I-domain of an α L subunit.

74. (currently amended) The antibody of claim 73, or an antigen binding fragment thereof, wherein said modified I-domain of an α L subunit contains amino acid substitutions K287C/K294C ~~or E284C/E301C~~.

75. (currently amended) The ~~anti-LFA-1~~ antibody of claim 31, or an antigen binding fragment thereof, wherein ~~said anti-LFA-1~~ the antibody, or an antigen binding fragment thereof selectively specifically binds to ~~a modified~~ an LFA-1 I-domain in the open conformation, relative to an LFA-1 I domain in the closed conformation, ~~wherein said modified LFA-1 I-domain contains amino acid substitutions K287C/K294C or E284C/E301C~~.

76. (currently amended) The antibody of claim 25 or 30, or an antigen binding fragment thereof, wherein said antibody comprises a portion of is a human antibody and a portion of a non-human antibody.

77. (previously presented) The antibody of claim 25 or 30, or an antigen binding fragment thereof, wherein said antibody is a humanized antibody.

78. (previously presented) The antibody of claim 25 or 30, or an antigen binding fragment thereof, wherein said antibody is a chimeric antibody.

79. (currently amended) ~~An antibody, or an antigen binding fragment thereof, which selectively binds to a modified I-domain of an α L subunit containing~~ The antibody of claim 73, or an antigen binding fragment thereof, wherein said modified I-domain of an α L subunit contains amino acid substitutions E284C/E301C.

80. (previously presented) The antibody of claim 25, wherein said antibody, or antigen binding fragment thereof, is identified by screening a phage display library with a modified integrin polypeptide, and isolating said antibody, or antigen binding fragment thereof.

81. (canceled)

82. (previously presented) The antibody of any one of claims 25, 30, or 79, wherein said antibody is a monoclonal antibody.

83. (new) An antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain in the open conformation but not to an integrin I-domain in the closed conformation.

84. (new) An antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain in the open conformation but not to a modified integrin I-domain that is locked in the closed conformation by the substitutions 289C/K294C.

85. (new) The antibody of claim 83, or antigen binding fragment thereof, which binds to a modified integrin I-domain in the open conformation but not to a modified integrin I-domain in the closed conformation.

86. (new) The antibody of claim 85 or antigen binding fragment thereof, wherein the modified integrin I-domain in the open conformation is modified by introduction of a disulfide bond.

87. (new) The antibody of claim 86 or antigen binding fragment thereof, wherein the modified integrin I-domain in the open conformation comprises substitutions E284C/E301C.

88. (new) The antibody of claim 86 or antigen binding fragment thereof, wherein the modified integrin I-domain in the open conformation comprises a substitutions K287C/K294C.

89. (new) A peptide ligand that binds to a modified integrin I-domain in the open conformation.

90. (new) The peptide ligand of claim 89 wherein the ligand does not bind to a modified integrin I-domain in the closed conformation.

91. (new) The peptide ligand of claim 89 wherein the modified integrin I-domain in the open conformation is modified by introduction of a disulfide bond.

92. (new) The peptide ligand of claim 89 wherein the modified integrin I-domain in the open conformation comprises the E284C/E301C or K287C/K294C substitutions.

93. (new) The peptide ligand of claim 89 wherein the modified integrin I-domain is an α L I domain.